Amisulpride
From Wikipedia, the free encyclopedia
| Image:Amisulpride.png | |
| Amisulpride
| |
| Systematic (IUPAC) name | |
| 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]- 5-ethylsulfonyl-2-methoxy-benzamide | |
| Identifiers | |
| CAS number | 53583-79-2 |
| ATC code | N05AL05 |
| PubChem | 2159 |
| DrugBank | none |
| Chemical data | |
| Formula | C17H27N3O4S |
| Mol. weight | 369.48 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 48% |
| Metabolism | ? |
| Half life | 12 h |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
B3(AU) |
| Legal status |
Prescription only |
| Routes | Oral, intramuscular |
Amisulpride (brand-name Solian®) is an antipsychotic drug sold by Sanofi-Aventis. Amisulpride is a selective dopamine antagonist. It has a high affinity for D2 (Ki 2.8 nM) and D3 (Ki 3.2 nM) dopaminergic receptors. Its dosage ranges from 200 to 1200 mg/day. Lower doses (less than 50mg) preferentially block d2 autoreceptors that control the synthesis and release of dopamine. This results in an increase in dopaminergic transmission. This dopamine increase is hypothesized to cause a reduction in both depressive and negative symptoms. Higher doses of the drug block the postsynaptic dopamine receptors resulting in an improvement in psychoses. Amisulpride is not approved by the Food and Drug Administration for use in the United States. Amisulpride (in 50mg doses) is marketed as a treatment for dysthymia in Italy (as Deniban) In one study, anxiety measured by HAM-A total mean score decreased significantly more with amisulpride 50mg/day (63%) than with fluoxetine 20mg/day (54%; P = 0.021).
[edit] Side effects
Prolactin induction, nausea, weight gain, although much less than similar drugs in its class, and less commonly QT interval prolongation (which can lead to serious heart arrhythmias).
[edit] See also
[edit] References
- ↑ BIAM (2000) AMISULPRIDE, (HTML) Banque de Données Automatisée sur les Médicaments [online] Available from: http://www.biam2.org/www/Sub393.html Accessed on 25 November 2005. (French)
- ↑ Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. (2002). "A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.". Human Psychopharmacology 17 (1): 1-13. PMID 12404702
- ↑ see Rosenzweig et al., 2002.
- ↑ see Rosenzweig et al., 2002.
- ↑ see BIAM, 2000.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9495601&dopt=Abstract
